Overview

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
Phase:
Phase 4
Details
Lead Sponsor:
Northern California Retina Vitreous Associates
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept